Forte Biosciences (FBRX) Capital Expenditures (2016 - 2025)

Forte Biosciences (FBRX) posted quarterly Capital Expenditures of $55000.0 for Q3 2025, down 9.84% quarter-over-quarter from $61000.0 in Q1 2025.

Forte Biosciences (FBRX) Capital Expenditures (2016 - 2025) Analysis & Trends

Forte Biosciences (FBRX) has reported Capital Expenditures for 7 consecutive years, with $55000.0 the latest figure, recorded in Q3 2025.

In Q3 2025, Capital Expenditures changed N/A year-over-year to $55000.0; the TTM figure through Mar 2026 stood at $55000.0 (down 40.22% YoY), while the FY2025 annual figure was $116000.0, up 213.51% from the prior year.
Capital Expenditures slipped to $55000.0 in Q3 2025 per FBRX's latest filing, from $61000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $61000.0 in Q1 2025 and bottomed at $6000.0 in Q1 2024.
Historically, Capital Expenditures has averaged $35166.7 across 3 years, with a median of $36000.0 in 2023.
Annual changes were most pronounced in 2024 — Capital Expenditures jumped 82.35% — and 2025, when it surged 916.67%.
Forte Biosciences' Capital Expenditures stood at $17000.0 in 2023, then surged by 82.35% to $31000.0 in 2024, then surged by 77.42% to $55000.0 in 2025.
Business Quant data shows FBRX's Capital Expenditures at $55000.0 in Q3 2025, $61000.0 in Q1 2025, and $31000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	2.29 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	25.02 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	572,662.23
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	251.02 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	34.68 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	6.26 Mn
10	Forte Biosciences	1.63 Bn	1.28 Bn	-	-

Download Data